title: Viking Therapeutics: The Prime Target In The Obesity Gold Rush
source: SeekingAlpha
date: 2025-10-23
url: https://finnhub.io/api/news?id=b9a82a43323d724bd37247a20ed5cf0728ad753ea2ec3a15956818d98315b03a
Viking Therapeutics focuses on metabolic therapies with a strong pipeline, takeover potential, and late-stage obesity drug VK2735. Check out why VKTX stock is a buy.
